AstraZeneca

Strategic Intent

AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals.

Key Market Signals

• 2024-10: Detention of China President Leon Wang amid medical insurance fraud investigation.
• 2025-02: Formal charges filed in China against AstraZeneca subsidiary for illegal trade and data privacy breaches.
• 2025-02: Announcement of $3.5B investment in US R&D and manufacturing.
• 2025-05: US Appeals Court affirms dismissal of AstraZeneca's lawsuit against Medicare price negotiations.
• 2025-12: Achievement of My Green Lab 2.0 certification for all global operational sites.

Financial Health

• 2024 Total Revenue reached $54.1B, a 21% increase at constant exchange rates (CER). Source: https://www.cision.com/news-releases/astrazeneca-6-february-2025-full-year-and-q4-2024-results-302369455.html
• Core Earnings Per Share (EPS) increased by 19% in FY 2024. Source: https://www.astrazeneca.com/media-centre/press-releases/2025/full-year-and-q4-2024-results.html
• Company projects continued growth momentum into 2025 with revenue expected to increase by a high single-digit to low double-digit percentage. Source: https://www.astrazeneca.com/investor-relations/results-and-presentations.html

Impact & Compliance

Legal & Risks

AstraZeneca faces significant regulatory and legal challenges in China involving allegations of medical insurance fraud, illegal drug importation, and data privacy breaches, leading to the indictment of its former China President and other executives in late 2024 and early 2025.

Forensic Audit — 2 findings

• Indictment of China subsidiary for unlawful collection of personal information and illegal trade involving cancer drugs ...
• Potential fines in China up to $8M for suspected unpaid import taxes related to Enhertu.

Classifications

Proprietary Analysis